Prof. Richard Greil MD
Head of the IIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria
Prof. Gabriel Rinnerthaler MD
IIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg Cancer, Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria
Prof. Simon P. Gampenrieder MD
IIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria
Prof. Peter Schmid FRCP MD PhD
Centre Lead, Centre for Experimental Cancer Medicine, Director, Breast Cancer, St Bartholomew, Hospital London, London, United Kingdom
Prof. Dipl.-Ing. Dr. Zlatko Trajanoski
Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Austria
Marleen Kok MD PhD
Medical Oncologist and Groupleader Tumor biology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands
Prof. Eric Vivier DVM PhD
Professor, Aix Marseille Univ, CNRS, INSERM, Centre d’Immunologie de Marseille-Luminy, Scientific Director- Innate Pharma Research Labs and President- Paris-Saclay Cancer Cluster, Marseille, France
Prof. Dr. Niels Schaft PhD
Research Group Leader of the RNA-based Immunotherapy group, Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Prof. Laurence Zitvogel MD PhD
Gustave Roussy Comprehensive Cancer Institute, Villejuif, France
Université Paris Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France, INSERM U1015, Villejuif, France
Prof. Dr. Fritz Aberger
Molecular Cancer and Stem Cell Research, Lab Department of Molecular Biology, University of Salzburg, Cancer Cluster Salzburg (CCS), Salzburg, Austria
Dr. Iosifina Foskolou
Group Leader at Sanquin Research, Amsterdam, The Netherlands
Emanuela Romano MD PhD
Medical Director, Center for Cancer Immunotherapy, Department of Oncology, INSERM U932, Institut Curie, Paris, France
Prof. Dr. Udo Gaipl
Head of Translational Radiobiology, Universitätsklinikum Erlangen, Department of Radiation Oncology, Erlangen, Germany
Dr. Roberto Salgado
Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium; Division of Research, Peter Mac Callum Cancer Center, Melbourne, Australia
Prof. Dr. Barbara Seliger
Director of the Institute for Medical Immunology, Martin Luther University, Medical Faculty, Halle, Germany
Karen Willard-Gallo MD PhD
Head, Molecular Immunology Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
Giampaolo Bianchini MD
Associate Professor – Università Vita-Salute San Raffaele, Head Breast Cancer Group – Department of Medical Oncology, Head clinical translational and immunotherapy research, Ospedale San Raffaele, Milano, Italy
12:30 – 13:30 Welcome & Business Lunch
13:30 – 13:35 Introduction
Richard Greil (Salzburg)
13:35 – 15:45 Combination strategies
Chair: Gabriel Rinnerthaler, Simon Gampenrieder
Immunotherapy in breast cancer: An overview of current strategies and perspectives
Richard Greil (Salzburg)
Immune checkpoint inhibitor + anti HER2
Gabriel Rinnerthaler (Salzburg)
Immune checkpoint inhibitor + ADC
Peter Schmid (London)
Dissecting tumor microenvironment, one cell at a time
Zlatko Trajanoski (Innsbruck)
Panel-Discussion
All speakers
Moderator: Richard Greil (Salzburg)
15:45 – 16:15 Coffee Break
16:15 – 18:30 Novel therapeutic approaches
Chair: Gabriel Rinnerthaler, Marleen Kok
Optimizing breast cancer immunotherapy
Marleen Kok (Amsterdam)
NK cell targeted therapy
Eric Vivier (Marseille)
CAR T-Cells
Niels Schaft (Erlangen)
Targeting the microbioma to improve immunotherapy efficacy
Laurence Zitvogel (Paris)
Panel-Discussion
All speakers
Moderator: Richard Greil (Salzburg)
08:30 – 10:15 Metabolism & Immunogenicity
Chair: Fritz Aberger, Richard Greil
2-hydroxyglutarate and other metabolites*
Iosifina Foskolou (Amsterdam)
The role of tumor-associated macrophages in breast cancer*
Emanuela Romano (Paris)
Abscopal effect – true or overrated?*
Udo Gaipl (Erlangen)
*Discussion after lecture
10:15 – 10:45 Coffee break
10:45 – 13:00 Biomarker
Chair: Simon Gampenrieder, Roberto Salgado
TILs vs PDL1: what is the best pragmatic approach in daily practices?
Roberto Salgado (Antwerp)
MHC class I loss
Barbara Seliger (Halle)
Tertiary lymphoid structures
Karen Willard Gallo (Brussels)
Immune Cell Composition
Giampaolo Bianchini (Milano)
Panel discussion
All speakers
Moderator: Richard Greil (Salzburg)
Closing Remarks
Richard Greil (Salzburg)
13:00 – 14:00 Business Lunch & Farewell
The registration form is now available, we look forward to your submission. We would like to point out that this conference is not open to the public. After your registration your entries will be checked by us, followed by information about your requested participation.
5th SALZBURG BREAST CANCER TALK – Mastering translational Immuno-Oncology is applied for 11 DFP points at the Diploma Continuing Education Programme of the Austrian Medical Association (ÖÄK).
Hotel Gersbergalm
Gersberg 37
5020 Salzburg
The hotel can be reached by car (sufficient parking available), by bus (line 151) or by cab (still city area).
Prof. Dr. Richard Greil
Dr. Simon P. Gampenrieder
Dr. Gabriel Rinnerthaler
Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT)
in Kooperation mit
Cancer Cluster Salzburg | www.cancercluster-salzburg.at
Photos: Franz Neumayr
POSTPONED DUE TO SARS-CoV-2 Due to the current situation concerning the coronavirus epidemic and the resulting travel restrictions of even already planned speakers, we have decided to reschedule our event „Salzburg Breast Cancer Talk“ to October 2022....
Die Veranstaltung 3rd SALZBURG BREAST CANCER TALK, MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY vom 01. bis 02.03.2019, im PITTER Event Center Salzburg war mit über 100 Teilnehmern wieder ein voller Erfolg. Die Vortragenden, alle auf ihrem Fachgebiet international renommierte Wissenschaftler, verstanden es eindrucksvoll, dem fachkundigen Publikum Einblicke in ihre Forschung am Puls der Zeit zu gewähren. Die Disskusionsrunden […]...
01.- 02.03.2019 Salzburg — MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY...
